RETLIRA 30 — 30mg / 3ml Research Pen
Retlira 30 — Retatrutide 30 mg Pre-Filled Pen
Triple-Receptor Research | Metabolic Health | Weight-Management Research
Product Overview
Retlira 30 is a pre-filled pen-format research product listed as containing 30 mg of retatrutide in a 3 ml presentation.
Retatrutide, also known as LY3437943, is an investigational peptide being studied for its activity across three metabolic hormone receptors: GLP-1, GIP and glucagon. These pathways are involved in appetite signalling, glucose regulation and energy metabolism.
Its triple-receptor mechanism has attracted significant scientific interest because researchers are investigating whether coordinated activity across these pathways can influence body-weight regulation and other metabolic outcomes.
Key Clinical Research Findings
1. Significant Body-Weight Reduction
A Phase 2 clinical trial published in The New England Journal of Medicine in 2023 evaluated retatrutide in 338 adults with obesity or overweight and a weight-related complication, excluding diabetes.
After 48 weeks, average body-weight reductions were:
-
1 mg trial group: 8.7%
-
4 mg trial group: 17.1%
-
8 mg trial group: 22.8%
-
12 mg trial group: 24.2%
The placebo group experienced an average reduction of 2.1%.
These results demonstrated substantial weight reduction in the studied population. They reflect a specific clinical trial and do not predict results from Retlira 30.
2. Triple-Receptor Activity
Retatrutide's defining research feature is its activity across GLP-1, GIP and glucagon receptors. Researchers are investigating how these pathways interact in the regulation of appetite, energy intake and energy expenditure.
This mechanism distinguishes retatrutide from compounds that target only GLP-1 or both GLP-1 and GIP receptors.
3. Waist Circumference and Body-Composition Research
In the Phase 2 trial, average waist-circumference reductions ranged from approximately 6.5 cm to 19.6 cm across the retatrutide groups, compared with 2.6 cm in the placebo group.
These findings provide additional evidence of changes in body measurements during the study. They should not be interpreted as guaranteed outcomes or as proof of specific changes in muscle mass or body composition.
4. Metabolic Health Research
Researchers are investigating retatrutide's potential effects on glucose regulation and other cardiometabolic markers. Its multi-receptor activity makes it an important subject of ongoing metabolic research.
However, the evidence remains under development, and further clinical trials are needed to establish its safety, long-term effects and potential clinical applications.